Interventional Cardiology Devices – Market Insights – Canada

Despite the negative impact of the COVID-19 pandemic in the short term, the Canadian IC device market will grow minimally through 2031, driven by an aging population, expanding CAD patient pool, an increasing prevalence of complex lesions, and the emergence of specialized premium-priced technologies to diagnose and treat these complex CADs—such as next-generation DES, BRS, and intravascular imaging catheters and pressure guidewires—supporting revenues. These areas of growth will offset ASP declines due to intense price competition across all market segments.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for IC devices in Canada, with market projections across a 12-year period.

A number of flagship devices were launched in recent years in the highly competitive DES market.

How have market dynamics changed between the three major competitors recently?

What competitive strategies are the major competitors implementing to gain share in this market?

What is the developmental pipeline for the next generation of BRS?

The continued launch of newer BRS and DCBs will drive a shift in device preference in procedures that have traditionally been performed with DES or BMS, respectively.

How are current recommendations for use dictating adoption of DES, BMS, and BRS for CAD patients?

What is the evolving role of DCBs in PCIs in the current clinical landscape?

Emerging technologies designed to diagnose and treat complex PCIs are expected to receive approval in Canada in the near future.

How will the adoption of alternative coronary physiology modalities such as resting indices, angiography-based FFR, and noninvasive FFRCT alter patient and procedure compositions in cardiac catheterization labs?

What is the status and expected impact of emerging balloon-based technologies such as DCBs and coronary lithotripsy?

The Canada IC device market has been impacted by the COVID-19 pandemic in the short term.

What factors have contributed to market declines?

To what degree has the pandemic affected different procedures and devices?

How soon will procedure volumes, sales, and revenues recover?

Table of contents